| P2093 | author name string | David G Parkes | |
| | Kenneth F Mace | |
| | Michael E Trautmann | |
| P2860 | cites work | A role for glucagon-like peptide-1 in the central regulation of feeding | Q24314317 |
| | Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor | Q24318252 |
| | Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 | Q24563957 |
| | Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice | Q24629441 |
| | Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 |
| | The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity | Q58448710 |
| | Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men | Q58448899 |
| | Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 |
| | Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2 | Q58449146 |
| | Standards of medical care in diabetes--2012 | Q24632533 |
| | Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review | Q27023364 |
| | Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors | Q28203273 |
| | Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis | Q28481242 |
| | Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 |
| | Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 |
| | Relationships of upper gastrointestinal motor and sensory function with glycemic control | Q32050159 |
| | Bioactive peptides from lizard venoms | Q34062907 |
| | Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis | Q34237350 |
| | Association of pancreatitis with glucagon-like peptide-1 agonist use. | Q34618507 |
| | Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies | Q34627077 |
| | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 |
| | Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function | Q35060123 |
| | Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes | Q35618856 |
| | Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies | Q35649213 |
| | Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy | Q35748345 |
| | Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 |
| | Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans | Q35913076 |
| | Physiology of GLP-1--lessons from glucoincretin receptor knockout mice | Q36012473 |
| | Effect of renal impairment on the pharmacokinetics of exenatide | Q36024667 |
| | Therapeutic approaches to preserve islet mass in type 2 diabetes | Q36366851 |
| | Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study | Q36420499 |
| | Fatty liver: a novel component of the metabolic syndrome | Q36906553 |
| | GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism | Q37078997 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | The incretin system and its role in type 2 diabetes mellitus | Q37266863 |
| | Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats | Q37368678 |
| | Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 |
| | Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus | Q37642377 |
| | Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection | Q37686556 |
| | A cohort study of acute pancreatitis in relation to exenatide use. | Q37841739 |
| | Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes | Q37900626 |
| | The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review | Q37954675 |
| | Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). | Q38324621 |
| | Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents | Q38340339 |
| | The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 |
| | Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia | Q38473330 |
| | Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. | Q39778606 |
| | A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells | Q40748616 |
| | Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure | Q41267217 |
| | Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 |
| | Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions | Q42450579 |
| | Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling | Q42454515 |
| | Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype | Q42478360 |
| | Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. | Q42492827 |
| | Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. | Q42506332 |
| | Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. | Q42520650 |
| | Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. | Q42524942 |
| | The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats | Q42533774 |
| | Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes | Q42660412 |
| | Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice | Q43064614 |
| | The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice | Q43231241 |
| | Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas | Q43276184 |
| | Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 |
| | Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro | Q43586628 |
| | Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor | Q43687822 |
| | The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes | Q43913927 |
| | Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice | Q44145661 |
| | Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. | Q44193794 |
| | Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy | Q44286369 |
| | Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. | Q44328972 |
| | Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes | Q44620317 |
| | Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). | Q44781512 |
| | Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes | Q44968815 |
| | Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight | Q45200771 |
| | Exenatide improves hypertension in a rat model of the metabolic syndrome | Q46042040 |
| | Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model | Q46159268 |
| | Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats | Q46509023 |
| | Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration | Q46740431 |
| | Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures | Q46988910 |
| | Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 |
| | Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats | Q47235596 |
| | Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice | Q47904088 |
| | The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. | Q47996706 |
| | Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs | Q48725317 |
| | Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene | Q50892144 |
| | The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. | Q51339510 |
| | Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. | Q51368060 |
| | Liraglutide as additional treatment for type 1 diabetes. | Q51372390 |
| | Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. | Q51578359 |
| | Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. | Q51581246 |
| | Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 |
| | Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. | Q52522147 |
| | Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. | Q53163778 |
| | Investigation of exenatide elimination and its in vivo and in vitro degradation. | Q53621094 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 219-244 | |
| P577 | publication date | 2012-12-12 | |
| P1433 | published in | Expert Opinion on Drug Discovery | Q5421204 |
| P1476 | title | Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. | |
| P478 | volume | 8 | |